Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Infinity Pharmaceuti (INFI)

Infinity Pharmaceuti (INFI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,758
  • Shares Outstanding, K 58,871
  • Annual Sales, $ 3,050 K
  • Annual Income, $ -47,060 K
  • 60-Month Beta 1.92
  • Price/Sales 21.05
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.15
  • Number of Estimates 3
  • High Estimate -0.10
  • Low Estimate -0.18
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9400 +17.55%
on 09/04/20
1.3282 -16.80%
on 08/24/20
-0.2150 (-16.29%)
since 08/21/20
3-Month
0.7800 +41.67%
on 07/14/20
1.3900 -20.50%
on 08/20/20
+0.2050 (+22.78%)
since 06/19/20
52-Week
0.6000 +84.17%
on 03/17/20
1.6800 -34.23%
on 01/23/20
-0.0850 (-7.14%)
since 09/20/19

Most Recent Stories

More News
Pacira (PCRX) Gains Positive CHMP Opinion for Exparel in EU

The CHMP gives a positive opinion recommending an approval for Pacira's (PCRX) Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.

IRWD : 9.59 (-4.10%)
PCRX : 59.16 (-2.65%)
INFI : 1.1050 (+0.45%)
ALDX : 7.01 (-5.65%)
Infinity to Present at Upcoming Investor Conferences in September

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase...

WFC : 23.84 (-5.13%)
INFI : 1.1050 (+0.45%)
Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of 20.00% and 80.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

INFI : 1.1050 (+0.45%)
Infinity: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Thursday reported a loss of $9.5 million in its second quarter.

INFI : 1.1050 (+0.45%)
Infinity (INFI) Up 4% Since Last Earnings Report: Can It Continue?

Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INFI : 1.1050 (+0.45%)
Infinity (INFI) Looks Good: Stock Adds 5.3% in Session

Infinity (INFI) saw a big move last session, as its shares jumped nearly 5% on the day, amid huge volumes.

INFI : 1.1050 (+0.45%)
ATXI : 11.33 (-1.48%)
Infinity Pharmaceuticals to Host a Virtual-Only 2020 Annual Meeting of Stockholders

--- To participate in the virtual meeting, stockholders must register by 11:59 ET on June 15, 2020 -

INFI : 1.1050 (+0.45%)
Infinity (INFI) Q1 Earnings Lag Estimates, IPI-549 in Focus

Infinity (INFI) posts a wider-than-expected loss for the first quarter of 2020.

RHHBY : 45.9900 (-1.81%)
BMY : 56.96 (-3.90%)
INFI : 1.1050 (+0.45%)
RCUS : 19.60 (-10.67%)
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -111.11% and 74.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

INFI : 1.1050 (+0.45%)
Infinity: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Monday reported a loss of $10.9 million in its first quarter.

INFI : 1.1050 (+0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade INFI with:

Business Summary

Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

See More

Key Turning Points

2nd Resistance Point 1.1267
1st Resistance Point 1.1133
Last Price 1.1050
1st Support Level 1.0733
2nd Support Level 1.0467

See More

52-Week High 1.6800
Fibonacci 61.8% 1.2674
Fibonacci 50% 1.1400
Last Price 1.1050
Fibonacci 38.2% 1.0126
52-Week Low 0.6000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar